

State of the ACTG Network

Judith Currier, MD
Co-PI and Network Chair
June 21, 2018



Namaste مرحبا Willkommen Bem Vindo Selamat Datang
Croeso
Bienvenidos Bienvenue Croeso Welcome Bienvenidos أهلا وسهلا
Benvenuti Welkom Bienvenue
Welkom Bienvenue Bem Vindo
Croeso
Namaste
أهلا وسهلا مرحبا
Selamat Datang Welcome Bienvenue Bem Vindo
Willkommen Willkommen Selamat Datang Croeso
Benvenuti Willkommen
Benvenuti Willkommen
Benvenuti
Καλώς ήλθατε

Completed Accrual

- 5263 KS Treatment
- 5278s Pk sub-studies of 5263 and 5264
- 5320 Hep C cohort
- 5329 HCT GT1 AbbVie
- 5332s Mechanistic sub-study REPRIEVE
- 5361s PREPARE sub-study REPRIEVE
- 5312 first cohort completed

Completed Follow-up

- 5315 Romidepsin
- 5335s Liver biopsy sub-study 5329
- 5337 Sirolimus
- 5350 Visbiome Probiotic
- 5336 Ruxolitinib

Opened and Close(er) to Opening

- 5366 Tamoxifen and Vorinostat (Women only)
- 5360 MinMon (Hep C)
- 5369 Gag conserved element therapeutic vaccine
- 5378 VRC01LS Single dose
- 5359 LA ART
- 5300B Phoenix
- 5356 Linezolid for MDR TB

In Development

- 5377 Tri-specific BNab
- 5375 Emergency Contraception with EFV and TB Rx
- 5376 Etonogestrel Implant DDI
- 5372 DDI DTG/Rifapentine
- 5373 INH Mono-resistant TB
- 5381 Obs DTG roll-out
- 5379 B-HIVE HBV vaccine
- 5380 PURGE-C (Acute Hep C)
- 5382 REP 2139-Mg Hep B cure
- 5364 Combination BNabs
- 5370 REGN2810 Anti-PD1 Ab
- 5368 Anti PD1 Ab for Hep B
- 5363 CVC for CVD
- 5362 Clofazimine for DS TB
- 5357 VRC01 + LA CAB
- 5355 CMV Vaccine

Proposals: PR, DACs, NWCS and DR

- Approved
 - 14 Proposals (PR)
 - 2 DACS
 - 11 DR
 - 16 NWCS


- Submitted by people “outside” the ACTG Network
 - 15 PR
 - 4 DACS
 - 17 NWCS
 - 6 DR

Accrual June 2017-May 2018

- 5314 participants enrolled
 - 3226 Interventional Trials (includes 2023 in REPRIEVE)
 - 2088 Observational and sub-studies

- 1765 US sites
- 3549 International Sites

Rolling Accrual



Abstracts and Publications

- 49 Abstracts presented
- 56 Manuscripts published
 - AIDS (9)
 - CID (8)
 - JID (7)
 - JAIDS (4)
 - Plos Path (2)
 - Science (1)

(Annals Int Med, J Clin Invest, J Virol, J Antimicrob Chem, J Wom Health, Anti Micro Chem, Sex Trans Dis, AIDS Res Hum Retro, others)

New Initiatives

- Protocol Chair support will start when concept approved to help support young investigators and allow effort to complete development more quickly (12/1/18)
- Communications Working Group Established in the AEC
 - To promote dissemination of results and openings of our studies
 - Pod casts of protocol chairs planned to discuss new studies opening
 - Development of lay summaries of all papers published
 - Improved access to publications on our website
- Lab Retreat held June 5-6th to improve integration of specialty labs into our scientific agenda

The next 4 days...

- Plenary sessions to showcase data from completed trials
- Awards to recognize important contributions to the group
- Think Tanks, Business Sessions and Symposia to generate discussion and seek and engagement on the scientific agenda
- New Investigator Workshop- an introduction to working in the ACTG
- Lab Symposium to highlight new horizons in lab research
- Trainings for several new studies
- Support committee meetings- discover what these important groups do
- Get involved, pack a lunch and enjoy- we need you!!

ACTG Leadership



Judith Currier
Network Chair



Joe Eron
Vice-Chair



Ian Sanne
International VC



Grace Aldrovandi
Lab Center PI



Sue Koletar
Chair, PEC



Michael Hughes
PI SDAC



Marlene Cooper
Director, DMC



Joanna Gervais
Interim Director LOC



Dan Kuritzkes
Past Chair, LOC Co- PI



Tina Brenneman
Director NCC